These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17904841)

  • 1. Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
    Paruch K; Dwyer MP; Alvarez C; Brown C; Chan TY; Doll RJ; Keertikar K; Knutson C; McKittrick B; Rivera J; Rossman R; Tucker G; Fischmann TO; Hruza A; Madison V; Nomeir AA; Wang Y; Lees E; Parry D; Sgambellone N; Seghezzi W; Schultz L; Shanahan F; Wiswell D; Xu X; Zhou Q; James RA; Paradkar VM; Park H; Rokosz LR; Stauffer TM; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6220-3. PubMed ID: 17904841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
    Dwyer MP; Paruch K; Alvarez C; Doll RJ; Keertikar K; Duca J; Fischmann TO; Hruza A; Madison V; Lees E; Parry D; Seghezzi W; Sgambellone N; Shanahan F; Wiswell D; Guzi TJ
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6216-9. PubMed ID: 17904366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
    Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
    J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and anti-tumor activities of some new pyridines and pyrazolo[1,5-a]pyrimidines.
    Ahmed OM; Mohamed MA; Ahmed RR; Ahmed SA
    Eur J Med Chem; 2009 Sep; 44(9):3519-23. PubMed ID: 19398146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
    Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases.
    Markwalder JA; Arnone MR; Benfield PA; Boisclair M; Burton CR; Chang CH; Cox SS; Czerniak PM; Dean CL; Doleniak D; Grafstrom R; Harrison BA; Kaltenbach RF; Nugiel DA; Rossi KA; Sherk SR; Sisk LM; Stouten P; Trainor GL; Worland P; Seitz SP
    J Med Chem; 2004 Nov; 47(24):5894-911. PubMed ID: 15537345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazolo[1,5-a]pyridines as p38 kinase inhibitors.
    Stevens KL; Jung DK; Alberti MJ; Badiang JG; Peckham GE; Veal JM; Cheung M; Harris PA; Chamberlain SD; Peel MR
    Org Lett; 2005 Oct; 7(21):4753-6. PubMed ID: 16209527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of pyrazolo[3,4-b]pyridine CDK1 inhibitors as anti-tumor agents.
    Lin R; Connolly PJ; Lu Y; Chiu G; Li S; Yu Y; Huang S; Li X; Emanuel SL; Middleton SA; Gruninger RH; Adams M; Fuentes-Pesquera AR; Greenberger LM
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4297-302. PubMed ID: 17532631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.
    Tucker TJ; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Reid JC; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
    J Med Chem; 2008 Oct; 51(20):6503-11. PubMed ID: 18826204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazolo[3,4-c]pyridazines as novel and selective inhibitors of cyclin-dependent kinases.
    Braña MF; Cacho M; García ML; Mayoral EP; López B; de Pascual-Teresa B; Ramos A; Acero N; Llinares F; Muñoz-Mingarro D; Lozach O; Meijer L
    J Med Chem; 2005 Nov; 48(22):6843-54. PubMed ID: 16250643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.
    Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Neumann U; Rucklin G
    Bioorg Med Chem Lett; 2006 Jan; 16(2):262-6. PubMed ID: 16249085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis of C-6 substituted pyrazolo[1,5-a]pyridines with potent activity against herpesviruses.
    Allen SH; Johns BA; Gudmundsson KS; Freeman GA; Boyd FL; Sexton CH; Selleseth DW; Creech KL; Moniri KR
    Bioorg Med Chem; 2006 Feb; 14(4):944-54. PubMed ID: 16213142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.
    Cho YS; Borland M; Brain C; Chen CH; Cheng H; Chopra R; Chung K; Groarke J; He G; Hou Y; Kim S; Kovats S; Lu Y; O'Reilly M; Shen J; Smith T; Trakshel G; Vögtle M; Xu M; Xu M; Sung MJ
    J Med Chem; 2010 Nov; 53(22):7938-57. PubMed ID: 21038853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facile synthesis and in-vitro antitumor activity of some pyrazolo[3,4-b]pyridines and pyrazolo[1,5-a]pyrimidines linked to a thiazolo[3,2-a]benzimidazole moiety.
    Abdel-Aziz HA; Saleh TS; El-Zahabi HS
    Arch Pharm (Weinheim); 2010 Jan; 343(1):24-30. PubMed ID: 19921685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
    Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
    Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
    Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
    Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.